52 results about "Melatonin receptor agonist" patented technology

Adenosine receptor agonists, particularly an agonist which binds to the A3 adenosine receptor, are used for induction of production or secretion of G-CSF within the body, prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenias; and inhibition of abnormal cell growth and proliferation.

The invention provides a medicine structurally containing a liver-targeting specific ligand and a thyroxine receptor agonist. The liver-targeting specific ligand and the thyroxine receptor agonist areconnected by branched chains, connectors and connecting chains to form a novel medicine structure. Thyroxine receptors (TRs) are divided into two subtypes, namely TR-alpha and TR-beta, wherein the TR-beta is mainly expressed in the liver, and the TR-alpha is mainly expressed in the heart, the nervous system and the like. In some embodiments, the medicine provided by the invention is expected to have a liver-targeting effect and can specifically bring the thyroxine receptor agonist into the liver so as to prevent the thyroxine receptor agonist from entering the heart and other tissues, so thatside effects triggered by the effect of the thyroxine receptor agonist on the other tissues can be avoided and the therapeutic effect of the medicine on treatment of lipid metabolism disorders and related complications is maintained.

This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.

Disclosed are A3 adenosine receptor antagonists and / or partial agonists and A1 adenosine receptor agonists and / or partial agonists of formula (I):wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The A3 AR antagonists or partial agonists find use in treating a number of diseases such as cancer, glaucoma, and inflammatory diseases, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs. The A1 AR agonists and partial agonists find use in treating diseases such as seizures, convulsion, stroke, diabetes, pain, arrhythmias, depression, and anxiety and in cardioprotection or neuroprotection.

The invention relates to N-(2-(substituted-naphth-1-yl)ethyl)-substituted amide compounds, and application of the same as melatonin receptor agonists and 5-HT2c receptor antagonists. Specifically, theinvention relates to the compounds as shown in a formula I which is described in the specification, or pharmaceutically acceptable salts or solvates thereof, or mixtures of the compounds, the salts and the solvates, and pharmaceutical compositions of the compounds, the salts, the solvates or the mixtures. X, R1, R2 in the formula I are as defined in the specification. The compounds as shown in the formula I of the invention can be used as melatonin receptor agonists and 5-HT2c receptor antagonists and is applicable to the preparation of drugs used for treating and / or preventing melatonin system diseases, stress, anxiety, seasonal affective disorders, cardiovascular diseases, digestive diseases, schizophrenia, phobias, depression, major depression, sleep disorders, sleep disturbance, insomnia or fatigue caused by jet lag, weight disorders and other diseases and illnesses.